Google
CERO — CERO THERAPEUTICS HOLDINGS, INC. COMMON STOCK (Healthcare >> Biotechnology)
CERO FAQ
What is CERO's ROE?
CERO THERAPEUTICS HOLDINGS, INC. COMMON STOCK reports a Return on Equity (ROE) of 223.57%.
What is CERO's dividend yield?
CERO THERAPEUTICS HOLDINGS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is CERO's Deepscope Quality Score?
Deepscope rates CERO's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CERO?
Deepscope's AI Timing Score for CERO is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CERO belong to?
CERO THERAPEUTICS HOLDINGS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.01
Price
0.00
(16.67%)
Day Change
|
|
|---|
CERO, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.01 |
| PBV / Sector |
-0.06 / 4.63
|
| Earning Per Share | -0.49 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.01 M
GREAT
|
| Average 1W Daily Value |
0.02 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:29 |
| Symbol | CERO |
| Name | CERO THERAPEUTICS HOLDINGS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 45.11 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 0.59 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 201 Haskins Way, South San Francisco, CA, United States, 94080
Phone: 650 407 2376
Website: https://www.cero.bio
Sector: Healthcare >> Biotechnology
Description: CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
